FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Real-time Bid/Ask 06:41:01 20/05/2024 pm IST | ||
| 8.41 EUR / 8.71 EUR | +2.76% |
|
| Current month | +36.56% | ||
| 1 month | +162.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 8.37 | +0.48% |
| 17/24/17 | 8.33 | -19.05% |
| 16/24/16 | 10.29 | +5.65% |
| 15/24/15 | 9.74 | +21.90% |
| 14/24/14 | 7.99 | +5.41% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 03:28 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4CZ9 |
| ISIN | DE000JK4CZ99 |
| Date issued | 22/03/2024 |
| Strike | 197.8 $ |
| Maturity | Unlimited |
| Parity | 3.77 : 1 |
| Emission price | 10.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.29 € |
|---|---|
| Lowest since issue | 2.88 € |
| Spread | 0.3 € |
| Spread % | 3.44% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Certificates
- Certificat
